IGFBP4 Protéine

N° du produit ABIN7849677

Protéine Recombinant IGFBP4 exprimée dans Escherichia coli (E. coli).

Aperçu rapide pour IGFBP4 Protéine (ABIN7849677)

Antigène: IGFBP4 (Insulin-Like Growth Factor Binding Protein 4 (IGFBP4))

Type de proteíne: Recombinant

Origine: Humain

Source: Escherichia coli (E. coli)

Application: Western Blotting (WB), SDS-PAGE (SDS), ELISA, Immunoprecipitation (IP)

Pureté: >90 % by SDS-PAGE

Détail du produit

Fonction: Recombinant Human IGFBP4 Protein

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: 20 mM Tris-HCl, 300 mM NaCl, pH 9.0 with 0.2 % SKL as the preservative.

Stock: 4 °C,-20 °C

Stockage commentaire: Ship at 4°C. Upon receipt, aliquot and store at -20°C for long term. Avoid repeated freeze and thaw cycles.

Détail du antigène

Antigène: IGFBP4 (Insulin-Like Growth Factor Binding Protein 4 (IGFBP4))

Autre désignation: IGFBP4

Sujet:

Synonyms: Insulin-like growth factor-binding protein 4, IGFBP4, IBP-4, IGF-binding protein 4, IGFBP-4, IBP4

Description: Recombinant human Insulin Like Growth Factor Binding 4 protein with molecular weight of 31.7 kDa.

Background: Insulin-like growth factor-binding protein 4 is a protein that in humans is encoded by the IGFBP4 gene.IGFBP4 maternal blood concentrations were lower during pregnancy than during non-pregnant cycles and synchronized control cycles. It can be speculated that the lower IGFBP4 in maternal blood may result in an increase of free IGF1 for local action. IGFBP4 downregulation in GCTs compared to MSCs. Overexpression of UCHL1 and IGFBP4 by stable transfection of GCTSC did not influence cell viability, proliferation, migration and chemosensitivity compared to parental cells. However, colony-formation was significantly decreased suggesting that rescue of UCHL1 and IFGBP4 suppresses clonogenicity of GCT stromal cells. Epigenetic silencing of UCHL1 and IGFBP4 in GCTs might thus be a crucial event during the malignant transformation of MSCs in the context of GCT development and represent promising targets for the development of new diagnostic and therapeutic strategies.

Pathways: Signalisation WNT, Myometrial Relaxation and Contraction, Regulation of Carbohydrate Metabolic Process